STAT Plus: Consumer groups and unions try again to block the AbbVie and Allergan merger
A coalition of consumer groups and unions hopes to convince the Federal Trade Commission to…
Category: finance
Watch: VCs have to predict the future. Here’s what three of them expect next in biotech
Biotech venture capitalists make their money by seeing the future better than most of us,…
STAT Plus: Microbiome-based drug makers are hoping new late-stage data will pull the field out of the shadows
The microbiome industry is on the cusp of a turning point. Seres Therapeutics, one of…
STAT Plus: A longtime health care investor recalls the insulin bong, praises discipline in valuations, and looks to South America
Les Funtleyder is a longtime health care investor who started his professional investing career just…
The Zolgensma lottery, billionaire philanthropy, & life on the buy side
What’s the right way to give drugs away? Is $3 billion even a lot of…
.jpg)
STAT Plus: Beam Therapeutics raises $180 million in IPO
Beam Therapeutics (BEAM), a Cambridge, Mass., genome-editing startup, raised $180 million in an initial public…
STAT Plus: This VC firm once pledged to never invest in health care. Now it’s launching its third life sciences fund
Marc Andreessen, famous for proclaiming that software was “eating the world,” said in 2009 that…
STAT Plus: Watch: CEO Daniel O’Day says Gilead is in a ‘sweet spot.’ What’s next?
What’s Gilead going to buy? That’s the single, persistent question Daniel O’Day has faced in…
Three star scientists announce plan to solve biotech’s ‘missing women’ problem
They are the biotech equivalent of the “missing girls” in countries with a skewed gender…
STAT Plus: Biotech earnings preview: Unsettled investors hoping for strong 2020 outlooks
Biotech earnings season kicks off Thursday with fourth-quarter reports from Alexion Pharma (ALXN), Amgen (AMGN),…
STAT Plus: ‘The gurus of sperm’: Ohana Biosciences is taking a different approach to fertility
“Ohana” means family in Hawaiian — and the new Cambridge, Mass.-based biotech that took that…
23andMe laying off 14% of employees amid slump in DNA spit kit sales
In the latest sign of a slump in consumer genetic testing, 23andMe is laying off…
STAT Plus: Many patient groups have deep ties to pharma but fail to disclose backing
Amid ongoing debate over the role the pharmaceutical industry plays in shaping health policy, a…
STAT Plus: A venture firm warms to funding neuroscience
Longtime venture capital star Beth Seidenberg and former Amgen R&D chief Sean Harper say they…
STAT Plus: Pharmalittle: Roche plans aggressive SMA drug pricing; where are those clinical trial results?
Good morning. Elizabeth Cooney here in Boston while Ed Silverman hobnobs with industry types at…
A forerunner in ‘smart pills’ adopts a new tack as key pharma partnership unravels
SAN FRANCISCO — It was supposed to be a showcase for the way in which…
.jpg)
Purdue, maker of OxyContin, quietly splits ways with PhRMA as it pulls back from lobbying
WASHINGTON — Purdue Pharma, the embattled opioid maker, has quietly split ways with PhRMA, the…
STAT Plus: In novel partnership with cancer group, biotech venture firm doles out grants for research
The whole point of a biotech venture capital firm is to make money for itself…
STAT Plus: Something Ventured: Akrevia Therapeutics and three other startups got venture funding a year ago. Did it help them do what they said it would?
This story is part of STAT’s quarterly series Something Ventured, which looks at early-stage startups….
STAT Plus: Acquisitions, not Congress, will chart biotech’s course in 2020, experts predict
Washington has never before been so focused on lowering prescription drug prices. But these biotech…
STAT Plus: Veritas, genetics company founded by George Church, suspends U.S. operations
Veritas Genetics, the Boston-based personal genome testing company co-founded by noted Harvard Medical School professor…
Opinion: Step aside, biomarkers. Look to the bank account for early signs of dementia
One crucial missing piece to the devastating puzzle of Alzheimer’s disease and other types of…
STAT Plus: Enlight Biosciences was going to ‘transform pharma R&D.’ What happened?
Unlike most biotech startups, Enlight Biosciences was never expected to make any drugs. Instead, the…
Having gobbled up Celgene, the Bristol-Myers CEO ducks questions about his key rival
CAMBRIDGE, Mass. — In his first appearance since Bristol-Myers Squibb completed its takeover last week…
STAT Plus: ‘The industry has earned it’: Three CEOs own up to biopharma’s bad reputation
CAMBRIDGE, Mass. — Biopharma’s reputation is, objectively speaking, the worst. And on Thursday, several biotech…
STAT Plus: Biotech venture capitalists form a lobbying coalition to join the drug pricing debate
A shorter version of this story first appeared in D.C. Diagnosis, STAT’s weekly newsletter about…
STAT Plus: Novo Nordisk’s parent company to launch research incubator in Boston
Novo Holdings, the investment firm behind pharmaceutical giant Novo Nordisk, is committing $25 million over…